Ashley E. Wagner

Silicon Valley
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA
Profile Experience

Ashley Wagner advises a wide variety of clients, including public and private companies, with respect to establishing:

  • Equity incentive plans
  • Deferred compensation and bonus plans
  • Severance and change in control arrangements
  • Employment agreements

In addition, her experience includes dealing with employee benefit and compensation aspects of merger and acquisition transactions, financings, initial public offerings (IPOs), and other corporate transactions.

Ms. Wagner is actively involved in the firm's pro bono program. Her pro bono work includes helping individuals obtain permanent restraining orders for domestic violence and advising non-profits on employee benefits matters, employee handbooks, classification of workers, executive compensation, and general employment labor matters.

She is a member of Latham's Women Lawyers Group and formerly served on the firm's Recruiting Committee.

Ms. Wagner's experience includes representing:

  • Thoratec, a developer and manufacturer of mechanical circulatory support technology for the treatment of advanced hart failure, in its US$3.475 billion sale to St. Jude Medical
  • CH2M Hill, an engineering company that provides consulting, design, construction, and operations services, in its US$3.27 billion sale to Jacobs Engineering
  • KYTHERA Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on aesthetic prescription products, in its US$2.1 billion sale to Allergan
  • Relypsa, a biopharmaceutical developer of non-absorbed polymeric drugs for treatment of cardiovascular and renal diseases, in its US$1.53 billion sale to Galenica
    Sale of Afferent Pharmaceuticals, a developer of pharmaceutical treatments for osteoarthritis, back pain, visceral pain and neuropathy, in its US$1.25 billion sale to Merck & Co
  • Integrated Device Technology in its US$250 million acquisition of GigPeak, a provider of semiconductor ICs and software solutions for high-speed connectivity and high-quality video compression over the network and the cloud
  • MyoScience, a medical device company, in its US$220 million sale to Pacira Pharmaceuticals
  • Bright Machine in its US$175 million Series A preferred stock financing
  • Canada Pension Plan Investment Board as an existing GlobalLogic shareholder in the Partners Group's acquisition of a 48% stake in GlobalLogic
  • Spectrum Equity in numerous transactions, including acquisitions, dispositions, and investments
  • Virgin America Inc. in their US$306 million IPO
  • Virgin America Inc. in its sale to to Alaska Air Group
  • Nevro Corp. in their US$144 million IPO
  • Satsuma Pharmaceuticals in their US$82.5 million IPO
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.